MSR gene therapy

Prolindox is developing a gene therapy platform focused on restoring the activity of Methionine Sulfoxide Reductase (MSR) enzymes. MSR enzymes, including MsrA and MsrB, play a critical role in cellular antioxidant defense by reducing methionine sulfoxide—the oxidized form of the amino acid methionine—back to its functional state. The accumulation of oxidized proteins is a hallmark of aging and is linked to the pathogenesis of various conditions, particularly neurodegenerative disorders like Alzheimer's and Parkinson's diseases, where protein misfolding and oxidative stress are prevalent. By utilizing a gene therapy approach to overexpress or restore MSR levels, Prolindox aims to enhance the endogenous protein repair machinery, potentially slowing disease progression or reversing damage in tissues affected by chronic oxidative stress. The program is currently in preclinical development.

Other names

MSR gene therapyMethionine sulfoxide reductase gene therapyProlindox MSR program